A comprehensive regional strategy
Addressing guidance on safe handling of hazardous drugs


Background
Occupational exposure to hazardous drugs (HDs) is a mounting public health concern. Nevertheless, currently there are no harmonised standards for the prevention of HDs’ exposure.

Purpose
To implement a comprehensive regional strategy (CRS) addressing guidance on safe handling of HDs in order to minimise healthcare workers’ exposure based on the harmonisation of safety standards and practices among hospitals.

Material and methods
A 32-item online questionnaire about general information, preparation and administration of HDs was carried out to investigate the current situation of training and awareness among workers of 34 regional public hospitals (RPH).

A multidisciplinary working group, involving 40 health professionals (including hospital pharmacists, oncology nurses, occupational medicine professionals and warehouse logistics managers) from 14 different hospitals was formed in 2017 to formally achieve consensus on the management of HDs.

A formal education plan was implemented, providing online and face-to-face train-the-trainers courses to all health professionals involved in the preparation and administration of HDs.

Results
Overall, survey results showed heterogeneous procedures concerning NIOSH table 1 drugs and deficiencies in training and in awareness regarding handling of the other HDs.

In January 2018 Resolution 51/2018 was published. This was the first formal European framework establishing mandatory practice standards on safe handling of HDs for 34 RPH.

One of the most remarkable points of Resolution 51/2018 is the creation of HDs’ Committees in each hospital, which ensure compliance with the reporting standards and promoting supplementary and specific protocols if necessary.

Additionally, the aforementioned resolution includes two monographic annexes on closed-system transfer devices and personal protective equipment. Further recommendations related to drug preparation, administration and reception, have been also carried out.

So far, 413 training-trainers have completed the formal education plan and 4155 healthcare workers have finished online training courses.

In April 2018 the CRS was presented at the European Parliament during the conference named ‘The problem of HDs in the healthcare sector in Europe’.

Conclusion
Protection from HDs’ exposure depends on adherence to safety programmes, as well as other factors.

A comprehensive approach based on the harmonisation of safety standards, the engagement in safety culture and appropriate practice techniques among hospitals could minimise worker exposure to HDs.

REFERENCES AND/OR ACKNOWLEDGEMENTS
Hazardous Drugs Working Group.
No conflict of interest.

Financial impact of third-generation cephalosporines resistance in hospital settings – an example with ceftriaxone

M Kamusheva, M Amenikova*, G Petrova, I Pencheva. Faculty of Pharmacy- Medical University – Sofia, Department of Organisation and Economics, Sofia, Bulgaria; Faculty of Pharmacy- Medical University – Sofia, Department of Pharmaceutical Chemistry, Sofia, Bulgaria

Background
Despite the availability of a national antibiotic stewardship programme, antibiotic resistance (AR) in local hospital settings has been increasing in recent years. The consumption of third-generation cephalosporins in national hospitals increased from 0.2 in 2006 to 0.8 in 2016 defined daily doses (DDD) per 1000 patients/day.

Purpose
The goal is to estimate the financial impact of cephalosporin resistance in patients with lower respiratory tract infections (LRTI) and to calculate the savings in case of regular application of antibigrams from the hospital perspective.

Material and methods
A cost-benefit analysis was applied to evaluate the benefits from the introduction of compulsory antibigrams in hospitals in case of LRTI. Information about the AR towards ceftriaxone was gathered from the National Reference Microbiology Centre. The cost of ceftriaxone and antibiotics commonly applied as alternatives (linezolid, vancomycin, teicoplanin) in the case of AR was calculated based on hospital prices. Cost per bed day and length of stay in hospitals were taken from the National Centre of Public Health and Analyses and the cost of antibigram from the National Health Insurance Fund. Savings from the avoided hospital stay, cost of therapy and antibigram for a cohort of 200 patients with LRTI were calculated.

Results
The level of ceftriaxone resistance is 8% (Pseudomonas aeruginosa) and 14% (Klebsiella pneumonia). The price per DDD of ceftriaxone is €1.93, its alternatives €22.54, the number of hospital days for treatment of LRTI is 9.94, the extension of hospital stays due to AR is five, the price of one hospital bed per day is €64.83 and the unit price of antibigram is €2.25. Thus, the total costs for treatment of LRTI patients are €99,256.57 with and €101,888.07 without

REFERENCE AND/OR ACKNOWLEDGEMENTS
No conflict of interest.

Abstracts

‘dangerous’ products, the analysis showed that 37% of these reagents present a high to very high risk, such as formaldehyde, 42% have a medium risk such as nitric acid and 21% pose a low to very low risk such as acetone.

Our second aim was to reduce risks, so we have proposed preventive measures such as the use of personal protective equipment (mask, gloves) and collective (hoods). The levels of risk have significantly decreased: 82% of the reagents with a very low risk and 12% have a medium risk. The products that have kept a very high severity are used rarely and in small quantities.

Conclusion
Our results concord with the literature. We have demonstrated that the level of severity of reagent is manageable by acting on two risk factors: the respect of the safety measure of each chemical and the exposure of the operator to the operations carried out.

REFERENCE AND/OR ACKNOWLEDGEMENTS
No conflict of interest.